Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies September 13, 2024Vol.50 No.34By McKenzie Prillaman
Trials & Tribulations A simple intervention could help address overlooked pain among older adults with cancer in rural America September 13, 2024Vol.50 No.34By Megan J. Shen
Trials & Tribulations Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations? September 06, 2024Vol.50 No.33By Rebecca Sutphen, Sue Friedman and Jon Florin
Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers June 28, 2024Vol.50 No.26By Matthew Bin Han Ong
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC June 07, 2024Vol.50 No.23By Jacquelyn Cobb and McKenzie Prillaman
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
